17 May 2023 | Wednesday | News
Image Source| Public Domain
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the manufacturing partnership with InflaRx for its COVID-19 treatment Gohibic (vilobelimab). InflaRx, a clinical-stage biopharmaceutical company headquartered in Jena, Germany developing anti-inflammatory therapeutics by targeting the complement system, received FDA emergency use authorization (EUA) in April 2023 for Gohibic for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).
Under the terms of the agreement, WuXi Biologics will provide cGMP manufacturing of Gohibic, a first-in-class monoclonal anti-human complement factor C5a antibody.
With a global manufacturing network that includes facilities in the United States, Ireland, Germany, China and Singapore, WuXi Biologics leverages its development and manufacturing technologies to provide more efficient and cost-effective production of drug substances (DS) and drug products (DP), delivering commercial biologics for global clients and enabling promising treatments delivered to patients worldwide.
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are proud of this manufacturing partnership with InflaRx for Gohibic. The partnership represents another remarkable milestone in our efforts to establish a robust manufacturing network on a global scale. We are fully committed to leveraging our global network, expertise and experience to make this important new treatment available as rapidly as possible to help improve the lives of many patients."
Prof. Niels C. Riedemann, CEO and Founder of InflaRx, commented, "We are pleased to collaborate with WuXi Biologics as our important manufacturing partner for Gohibic. Together we will now ramp up production under high pressure to roll out supply in order to serve the patient population in need as soon as possible. With its advanced technologies and proven expertise, WuXi Biologics has helped us enormously in our application to the FDA for Gohibic's emergency use authorization. We look forward to continuing this important manufacturing partnership to potentially benefit patients in additional other areas of the world."
© 2024 Biopharma Boardroom. All Rights Reserved.